Clinical Trial Update: Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study evaluating nilotinib combined with ruxolitinib in TKI-resistant Philadelphia chromosome-positive leukemias; trial status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Accelerated-phase Chronic Myeloid Leukemia
• Blastic-phase Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia
• Phase Chronic Myeloid Leukemia
• Philadelphia-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Nilotinib (nilotinib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED